Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Rydex Basic Biotechnology Fund Class H (RYOAX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks to provide capital appreciation. Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.


1 month+2.69% 3 years+10.46%
3 months+10.31% 5 years+17.54%
1 year+9.70% Since inception+11.32%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return+17.54%+16.30%
Expense ratio1.65%1.33%
Risk 5 year sharpe ratio0.791.05
Net assets$317.6M$3.0B
Average market cap$12.7B$29.5B
Average P/E21.424.1
Portfolio turnover83%83%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyRydex Funds
Fund manager & tenureMichael Byrum / 19 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00


U.S. stock98.89%
International stock0.00%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
AMGN Amgen5.70%
ABBV AbbVie5.50%
CELG Celgene5.27%
GILD Gilead Sciences5.06%
BIIB Biogen4.21%
SHPG Shire3.83%
REGN Regeneron Pharmaceuticals3.46%
VRTX Vertex Pharmaceuticals Inc3.10%
ILMN Illumina Inc2.85%
ALXN Alexion Pharmaceuticals Inc2.80%